| Revenue growth | 71.59% YoY to ₹8,346.21 lakh |
|---|---|
| Margins | EBITDA margin 12.29%, up 58 bps; PAT margin 8.44% |
| Order book | SI ₹8,066.96 lakh; VAD ₹2,789.23 lakh under execution |
| Demand visibility | Ongoing SI projects; NHAI CCM order due March 2027 |
Growth
Revenue +71.59% to ₹8,346.21 lakh; EBITDA +80.02% to ₹1,025.37 lakh; PAT +126.29% to ₹704.19 lakh.
Outlook
No explicit numeric guidance. Delhi Metro Phase-IV ~85% complete; Nasik parking due July 2027; NHAI CCM due March 2027.
Risks
Trade receivables ₹5,823 lakh form bulk of assets. Total borrowings rose to ~₹1,650 lakh from ~₹697 lakh.
Investor Presentation filed with NSE, NSE: MARUSHIKA. Summary written with AI assistance from the document.
Marushika Technology Ltd: key numbers
- Share price
- ₹120.00
- Market cap
- ₹102.4 Cr
- Revenue (annual)
- ₹116.4 Cr
- Net profit (annual)
- ₹8.95 Cr
- P/E (TTM)
- 11.4×Sector 23.8×
- Promoter holding
- 58.19%
- FII holding
- 5.58%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marushika Technology Ltd
All →Marushika Technology Earnings Call Transcript: Key Takeaways
H1 FY27 revenue ₹83.46 Cr (+71.6%) and PAT ₹7.04 Cr (+126.3%) on government project execution. Margin sustainability and defence answers gave no numbers. The ₹170 Cr FY27 target is the only hard guide.
Marushika Technology Results Update
Marushika reported H1 FY27 revenue growth of 71.59% and net profit growth of 126.30% year-on-year. The release shows highlights only, not a full results statement.
Marushika Technology H1 FY27 Results: Net Profit ₹7 Cr, Up 125.8% YoY
Marushika Technology Ltd reported revenue from operations of ₹83.5 Cr (+71.8% YoY) and net profit of ₹7 Cr (+125.8% YoY) for H1 FY27.
- Key figure
- Net profit ₹7 Cr · +125.8% YoY
Marushika Technology Other Announcement
Marushika Technology filed a Reg 27(2) non-applicability certificate for corporate governance for the half-year ended September 30, 2026. As an NSE Emerge-listed SME, the corporate governance provisions do not apply to it.
Marushika Technology Annual General Meeting
Marushika Technology Limited held its 16th Annual General Meeting on September 25, 2026. The meeting covered the adoption of financial statements and various board appointments.
Marushika Technology Partnership
Marushika Technology commenced a partnership with Sanare Medical as exclusive distributor of ExoAtlet II. The agreement targets government procurement via GeM across Indian public institutions.